Half-life
The time required for plasma concentration of a compound to fall to half its initial value.
Half-life (t½) is the time required for the plasma concentration of a compound to fall to half its initial value. It's a fundamental pharmacokinetic parameter that determines dosing frequency: a drug typically reaches steady state after 4-5 half-lives, and steady-state concentrations are predictable from dose × frequency × half-life. Natural peptides have very short half-lives (GLP-1: ~1-2 min; GHRH: ~7 min) due to rapid enzymatic degradation. Engineered research peptides extend half-life through modifications: lipidation (semaglutide ~7 days), albumin binding (CJC-1295 with DAC ~6-8 days), Fc fusion, or pegylation.
- GlossaryPhase 3
The penultimate stage of clinical drug development — large randomised trials testing efficacy and safety against existing standards of care.
- GlossaryPharmacokinetics
How the body absorbs, distributes, metabolises, and eliminates a compound — "what the body does to the drug."
- GlossaryPharmacodynamics
"What the drug does to the body" — the relationship between concentration and effect.
- ResearchCJC-1295 with DAC 5 mg
CJC-1295 with Drug Affinity Complex (DAC) — an extended GHRH analogue designed for half-life extension through covalent albumin binding.
- ResearchIGF-1 LR3 1 mg
Long R3 IGF-1 — an engineered IGF-1 analogue with reduced affinity for IGF-binding proteins and extended plasma half-life. Widely used research reagen